(Q34577226)

3 August 2017

1 reference

title

Antibody-directed enzyme prodrug therapy (ADEPT) for cancer (English)

1 reference

3 August 2017

1 reference

Kenneth D Bagshawe

1

1 reference

3 August 2017

1 October 2006

1 reference

Expert Review of Anticancer Therapy

3 August 2017

1 reference

3 August 2017

6

1 reference

3 August 2017

1421-1431

1 reference

3 August 2017

10

1 reference

Antibody directed enzymes revive anti-cancer prodrugs concept

3 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

A cytotoxic agent can be generated selectively at cancer sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Does P-glycoprotein play a role in anticancer drug pharmacokinetics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

The complete nucleotide sequence of the Pseudomonas gene coding for carboxypeptidase G2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

The clinical value of imaging with antibody to human chorionic gonadotrophin in the detection of residual choriocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Phage libraries for generation of clinically useful antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Altered biodistribution of an antibody--enzyme conjugate modified with polyethylene glycol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Prolonged in vivo residence times of antibody fragments associated with albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Covalent linkage of carboxypeptidase G2 to soluble dextrans--I. Properties of conjugates and effects on plasma persistence in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Covalent linkage of carboxypeptidase G2 to soluble dextrans--II. In vivo distribution and fate of conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Secreted and tumour targeted human carboxylesterase for activation of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Carboxypeptidase-mediated release of methotrexate from methotrexate alpha-peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Monoclonal anti-idiotypic antibodies as functional internal images of enzyme active sites: production of a catalytic antibody with a cholinesterase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

In vitro abzyme evolution to optimize antibody recognition for catalysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Activation of methotrexate-.alpha.-alanine by carboxypeptidase A monoclonal antibody conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Monoclonal antibody-beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

A strategy for tumor-selective chemotherapy by enzymatic liberation of seco-duocarmycin SA-derivatives from nontoxic prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Suicide gene therapy: conversion of ethanol to acetaldehyde mediated by human beta 2 alcohol dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

Therapeutic antibody fragments with prolonged in vivo half-lives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1421

10.1586/14737140.6.10.1421

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

17069527